Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.2%

1 terminated out of 46 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed with results

Key Signals

2 with results93% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (6)
Early P 1 (1)
P 1 (11)
P 2 (17)
P 3 (2)
P 4 (1)

Trial Status

Recruiting18
Completed13
Active Not Recruiting8
Not Yet Recruiting3
Unknown3
Terminated1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT04172805Phase 2CompletedPrimary

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

NCT05167994Phase 2RecruitingPrimary

Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma (SPARE-01)

NCT04605770Phase 2RecruitingPrimary

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

NCT04216953Phase 1CompletedPrimary

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

NCT05813327Phase 1Active Not Recruiting

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

NCT04577014Phase 1Recruiting

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

NCT04219202Not ApplicableRecruitingPrimary

Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion

NCT03474094Phase 2Active Not RecruitingPrimary

Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

NCT06712433Phase 2Not Yet RecruitingPrimary

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

NCT04122872Recruiting

GISAR German Interdisciplinary Sarcoma Registry

NCT06660810Phase 2Active Not Recruiting

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

NCT04616248Phase 1Active Not Recruiting

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT06835049Phase 2RecruitingPrimary

Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

NCT05235100Phase 2CompletedPrimary

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma (SPARE-02)

NCT06128863Phase 2Active Not Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

NCT06941194Not ApplicableRecruiting

Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery

NCT07027423Phase 1Not Yet Recruiting

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

NCT05886634Phase 2Active Not Recruiting

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

NCT05515575Phase 2Active Not RecruitingPrimary

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

NCT05296564Phase 1Recruiting

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Scroll to load more

Research Network

Activity Timeline